MX2020012700A - Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida. - Google Patents

Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida.

Info

Publication number
MX2020012700A
MX2020012700A MX2020012700A MX2020012700A MX2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A
Authority
MX
Mexico
Prior art keywords
acid sphingomyelinase
pharmaceutical compositions
treating acid
sphingomyelinase deficiency
compositions
Prior art date
Application number
MX2020012700A
Other languages
English (en)
Spanish (es)
Inventor
Claudia Buser
Mark Yang
Ramirez Bernardo Perez-
Grant Trierweiler
Sangeeta Benjwal
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2020012700A publication Critical patent/MX2020012700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2020012700A 2018-05-25 2019-05-24 Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida. MX2020012700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676525P 2018-05-25 2018-05-25
PCT/US2019/033983 WO2019227029A1 (en) 2018-05-25 2019-05-24 Pharmaceutical compositions for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
MX2020012700A true MX2020012700A (es) 2021-04-28

Family

ID=66912954

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012700A MX2020012700A (es) 2018-05-25 2019-05-24 Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida.
MX2025002733A MX2025002733A (es) 2018-05-25 2020-11-25 Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025002733A MX2025002733A (es) 2018-05-25 2020-11-25 Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida

Country Status (15)

Country Link
US (1) US20210145941A1 (cg-RX-API-DMAC10.html)
EP (1) EP3802805A1 (cg-RX-API-DMAC10.html)
JP (3) JP7497300B2 (cg-RX-API-DMAC10.html)
KR (1) KR102852946B1 (cg-RX-API-DMAC10.html)
CN (1) CN112424347A (cg-RX-API-DMAC10.html)
AU (2) AU2019275109C1 (cg-RX-API-DMAC10.html)
BR (1) BR112020023829A2 (cg-RX-API-DMAC10.html)
CA (1) CA3101688A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020014399A2 (cg-RX-API-DMAC10.html)
IL (1) IL278964A (cg-RX-API-DMAC10.html)
MX (2) MX2020012700A (cg-RX-API-DMAC10.html)
PY (1) PY1939780A (cg-RX-API-DMAC10.html)
SG (1) SG11202011488WA (cg-RX-API-DMAC10.html)
UY (1) UY38238A (cg-RX-API-DMAC10.html)
WO (1) WO2019227029A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022214529A1 (en) * 2021-02-01 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of niemann pick type a disease
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
CN1897957A (zh) * 2003-11-25 2007-01-17 纽约大学西奈山医学院 尼曼-皮克病的基于陪伴分子的治疗
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2391657T3 (es) * 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
BRPI0708879A2 (pt) * 2006-03-13 2011-06-14 Encysive Pharmaceuticals peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
AU2007226582B2 (en) * 2006-03-13 2012-07-05 Revvity Health Sciences, Inc. Substrates and internal standards for mass spectroscopy detection
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
JP6073783B2 (ja) * 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
MX338436B (es) 2011-03-31 2016-04-18 Medy Tox Inc Preparacion liofilizada de toxinas de botulismo.
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Also Published As

Publication number Publication date
SG11202011488WA (en) 2020-12-30
KR102852946B1 (ko) 2025-09-02
CO2020014399A2 (es) 2020-12-10
AU2019275109B2 (en) 2025-04-17
WO2019227029A1 (en) 2019-11-28
AU2025205577A1 (en) 2025-08-07
US20210145941A1 (en) 2021-05-20
KR20210015903A (ko) 2021-02-10
UY38238A (es) 2019-12-31
AU2019275109A1 (en) 2021-01-21
CA3101688A1 (en) 2019-11-28
JP2024069459A (ja) 2024-05-21
JP7497300B2 (ja) 2024-06-10
MX2025002733A (es) 2025-04-02
JP2026086903A (ja) 2026-05-26
AU2019275109C1 (en) 2025-11-13
IL278964A (en) 2021-01-31
CN112424347A (zh) 2021-02-26
JP7832245B2 (ja) 2026-03-17
JP2021525083A (ja) 2021-09-24
EP3802805A1 (en) 2021-04-14
PY1939780A (es) 2019-12-04
BR112020023829A2 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12018502634A1 (en) Topical compositions of apremilast
MX2025009223A (es) Agentes de union a clec9a y su uso
ZA202002094B (en) Trispecific proteins and methods of use
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
IN2015DN00376A (cg-RX-API-DMAC10.html)
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
PH12014500685B1 (en) Treatment of degenerative joint disease
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
PL3672622T3 (pl) Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
MX2021000037A (es) Nueva formulacion estable de alta concentracion para anticuerpos anti-fxia.
PH12021550122A1 (en) Solubilized apyrases, methods and use
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MY173174A (en) Short bio-active peptides for promoting wound healing
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2025002733A (es) Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.